Control of secondary hyperparathyroidism during long-term hemodialysis.
D000284:Administration, Oral; D000535:Aluminum / Q000008:administration & dosage; D002118:Calcium / Q000008:administration & dosage / Q000097:blood; D005260:Female; D006801:Humans; D006878:Hydroxides / Q000008:administration & dosage; D006961:Hyperparathyroidism / Q000150:complications / Q000209:etiology / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D010002:Osteitis Fibrosa Cystica / Q000209:etiology; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*
D006878:Hydroxides; D010710:Phosphates; D000535:Aluminum; D002118:Calcium